Zentalis Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	803	1,072	1,149	3,808	2,109
Market Cap Growth	-	-6.72%	-69.82%	80.54%	-
Enterprise Value	360	630	755	3,510	1,771
PE Ratio	-3.67	-3.67	-4.85	-23.99	-17.90
PB Ratio	1.84	2.45	2.65	10.46	6.84
P/FCF Ratio	-5.14	-5.14	-6.91	-23.77	-24.09
P/OCF Ratio	-5.16	-5.16	-7.02	-24.71	-24.30
EV/EBITDA Ratio	-2.16	-2.16	-3.20	-22.15	-15.10
EV/EBIT Ratio	-2.15	-2.15	-3.18	-22.07	-15.08
EV/FCF Ratio	-3.02	-3.02	-4.54	-21.91	-20.22
Debt / Equity Ratio	0.10	0.10	0.10	0.12	0.00
Debt / EBITDA Ratio	-0.15	-0.15	-0.19	-0.28	-0.01
Debt / FCF Ratio	-0.21	-0.21	-0.27	-0.28	-0.01
Quick Ratio	7.00	7.00	7.77	7.80	11.90
Current Ratio	7.16	7.16	7.98	7.98	12.07
Return on Equity (ROE)	-63.90%	-63.90%	-57.40%	-50.80%	-61.50%
Return on Assets (ROA)	-52.00%	-52.00%	-46.40%	-42.30%	-42.70%
Return on Capital (ROIC)	-62.34%	-62.34%	-47.45%	-53.02%	-38.36%
Earnings Yield	-36.41%	-27.25%	-20.60%	-4.17%	-5.59%
FCF Yield	-25.97%	-19.44%	-14.47%	-4.21%	-4.15%
Buyback Yield / Dilution	-23.75%	-23.75%	-23.82%	-51.84%	-402.29%
Total Shareholder Return	-23.75%	-23.75%	-23.82%	-51.84%	-402.29%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).